The publication of the Women’s Health Initiative study in 2002 changed forever the previous concepts of menopause management.
Even women with troublesome symptoms were often reluctant to consider hormone therapy given the increased risk of breast cancer found in this study. Since then there has been an attempt to put all risks in perspective when discussing the pros and cons of menopausal hormone therapy with a woman experiencing significant vasomotor symptoms.
From the initial maxim of the ‘lowest dose for the shortest time’ we moved to treating women with the dose of hormone therapy which effectively manages the symptoms for the time required. Then came the Lancet publication of August 2019 which not only re-emphasised the increased risk of breast cancer associated with hormone therapy but suggested that the risk is apparent even after only very short periods of use.
This educational activity will discuss the implications of the Lancet article for menopause management in Australia within the broader context of the risks and benefits of menopausal hormone therapy generally.
Based on this educational activity, complete these learning modules to gain additional CPD.
Palpitations – A Practical Approach for Primary Care
Bone Health in Menopausal Women – Is MHT Enough?
Sun-Related Skin Damage – Current Management Options
RSV Vaccination Update
Browse the latest videos from Healthed.
In this Product Explainer, Infectious Diseases Physician and Microbiologist A/Prof Paul Griffin explains the role of oral anti-virals in the context of the current COVID-19 virology and available therapies.
In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).